AI assistant
Coherus Oncology, Inc. — Director's Dealing 2019
Jan 14, 2019
33711_dirs_2019-01-14_bef3ef49-b171-4387-bc45-28752d470211.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Coherus BioSciences, Inc. (CHRS)
CIK: 0001512762
Period of Report: 2018-11-16
Reporting Person: Vexler Vladimir (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.0001 par value | 10800 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.0838 | 2023-02-28 | Common Stock (71982) | Direct | |
| Stock Option (right to buy) | $29.00 | 2025-04-01 | Common Stock (25000) | Direct | |
| Stock Option (right to buy) | $14.43 | 2026-02-26 | Common Stock (25000) | Direct | |
| Stock Option (right to buy) | $17.17 | 2026-05-11 | Common Stock (24618) | Direct | |
| Stock Option (right to buy) | $20.15 | 2027-04-03 | Common Stock (25000) | Direct | |
| Stock Option (right to buy) | $12.70 | 2027-08-06 | Common Stock (50000) | Direct | |
| Stock Option (right to buy) | $9.30 | 2027-11-15 | Common Stock (25000) | Direct | |
| Stock Option (right to buy) | $10.05 | 2028-02-01 | Common Stock (75000) | Direct |
Footnotes
F1: This Form 3 amendment has been filed solely to correct the amount of securities beneficially owned as shown in Table I, column 2.
F2: The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof.
F3: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F4: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F5: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F6: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F7: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F8: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F9: A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.